DUBLIN – Meiragtx Holdings plc remains on course to move its second-generation adeno-associated virus (AAV)-based gene therapy for inherited retinal disorders arising from RPE65 (retinal pigment epithelium-specific 65 KDa protein) deficiency into a pivotal trial shortly, following a six-month readout from a phase I/II trial in which the construct met the primary endpoint of safety and tolerability and achieved statistical significance on several measures of clinical activity.